Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (8
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30
Squarepoint Ops LLC Has $1.21 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX
05:03am, Sunday, 21'st Dec 2025
Squarepoint Ops LLC lessened its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 69.8% during the second quarter, according to the company in its most recent filing with the Se
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Thursday, 18'th Dec 2025
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will pr
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
04:05pm, Thursday, 11'th Dec 2025
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH Phase 3 study builds on positive phase 2 results showing
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:34pm, Wednesday, 10'th Dec 2025
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non
Capital Fund Management S.A. Makes New $424,000 Investment in Crinetics Pharmaceuticals, Inc. $CRNX
03:58am, Saturday, 06'th Dec 2025
Capital Fund Management S.A. acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in the second quarter, according to its most recent filing with the Securities and Exchange Commi
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with
Fisher Asset Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX
04:36am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC decreased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 4.7% in the second quarter, according to its most recent disclosure with the Securities and Exch
Creative Planning Sells 1,445 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
04:11am, Tuesday, 02'nd Dec 2025
Creative Planning lowered its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 4.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commiss
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
01:23pm, Thursday, 27'th Nov 2025
Boston-based MPM BioImpact sold 428,975 shares of Crinetics Pharmaceuticals worth about $12.3 million in the third quarter. The move marked a full exit for MPM, which reported holding no shares of CRN
Geode Capital Management LLC Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX
04:18am, Monday, 24'th Nov 2025
Geode Capital Management LLC boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 1.0% in the undefined quarter, according to the company in its most recent 13F filing with the Secur
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
04:05pm, Thursday, 20'th Nov 2025
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics' commitment to addressing unmet needs in the neuroendocrine tumor community
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:28pm, Monday, 10'th Nov 2025
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-
